Table 2. Immunosuppressive medication before and after conversion.

	Belatacept-treated patients (n = 19)
Induction at transplants
Anti-interleukin 2 receptor blocker, n (%)	7 (36.8)
Rabbit anti-thymocyte globulin, n (%)	12 (63.2)
Maintenance therapy before conversion
Tacrolimus, n (%)	19 (100)
Mycophenolate mofetil, n (%)	18 (94.7)
Azathioprine, n (%)	1 (5.3)
Steroids, n (%)	19 (100)
Tocilizumab, n (%)	3 (15.8)
Immunosuppressive therapy after conversiona
TAC, n (%)	19 (100)
MMF, n (%)	9 (47.4)
AZA, n (%)	1 (5.3)
Steroids, n (%)	19 (100)
Tocilizumab, n (%)	3b (15.8)

^a at the end of follow up

^b 2 patients started Tocilizumab after conversion to belatacept. 2 patients stopped Tocilizumab before the end of follow up